References
- Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe. Eur J Neurol 2006;13:333–45
- Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57
- Morillo LE, Alarcon F, Aranaga N, et al. Prevalence of migraine in Latin America. Headache 2005;45:106–17
- MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 2003;43:19–26
- Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57:418–20
- Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005;6:429–40
- Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003;23:441–50
- Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia 2002;22:680–5
- Vicente-Herrero T, Burke TA, Lainez MJ. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin 2004;20:1805–14
- Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 2003;23:429–40
- Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–8
- MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase III. Curr Med Res Opin 2004;20:1143–50
- Pradalier A, Auray JP, El Hasnaoui A, et al. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. Pharmacoeconomics 2004;22:985–99
- Dueland AN, Leira R, Burke TA, et al. The impact of migraine on work, family, and leisure among young women – a multinational study. Curr Med Res Opin 2004;20:1595–604
- Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87–96
- Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:885–94
- Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46:715–25
- Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003;60:441–8
- Goadsby PJ. Recent advances in the diagnosis and management of migraine. Br Med J 2006;332:25–9
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633–58
- Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355–63
- Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638–45
- Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43:S6–S10
- Dowson AJ, Tepper SJ, Baos V, et al. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 2004;20:1125–35
- Kilminster SG, Dowson AJ, Tepper SJ, et al. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache 2006;46:553–62
- Osterhaus JT, Townsend RJ, Gandek B, Ware Jr JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337–43
- Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999;19:107–14
- Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 2001;56:S20–S28
- Chatterton ML, Lofland JH, Shechter A, et al. Reliability and validity of the migraine therapy assessment questionnaire. Headache 2002;42:1006–15
- Garcia ML, Baos V, Láinez MJA, et al. Responsiveness of Migraine-ACT and MIDAS questionnaires for assessing migraine therapy: a 3-month, open-label, prospective study of patients in primary care in Spain. Headache [accepted for publication]
- Anon. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1):9–160
- Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963–74
- Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther 2003;25:2053–69